These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20005982)

  • 21. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.
    Vasiliauskas EA; Church JA; Silverman N; Barry M; Targan SR; Dubinsky MC
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1255-8. PubMed ID: 17045211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dacryoadenitis, an extra-intestinal manifestation of Crohn's disease.
    Wong JC; Rossman D; Bressler B
    Am J Gastroenterol; 2010 Aug; 105(8):1904-6. PubMed ID: 20686473
    [No Abstract]   [Full Text] [Related]  

  • 27. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
    Jordan N; Waghmare A; Abi-Ghanem AS; Moon A; Salvatore CM
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):294-6. PubMed ID: 21694635
    [No Abstract]   [Full Text] [Related]  

  • 28. [The cost effectiveness of adalimumab in Crohn's disease (review of foreign pharmacoeconomic studies)].
    Rudakova AV
    Eksp Klin Gastroenterol; 2011; (9):113-9. PubMed ID: 22629787
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab.
    Quin A; Kane S; Ulitsky O
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):278-81. PubMed ID: 18364718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immune reconstitution syndrome in a case of disseminated tuberculosis after withdrawal of treatment with adalimumab].
    Jorge-Ripper C; Pelazas R; González-Pérez JM; Santolaria F
    Rev Clin Esp; 2012 Apr; 212(4):219-21. PubMed ID: 22386757
    [No Abstract]   [Full Text] [Related]  

  • 32. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
    Nichita C; Stelle M; Vavricka S; El-Wafa Ali A; Ballabeni P; de Saussure P; Straumann A; Rogler G; Michetti P
    Digestion; 2010; 81(2):78-85. PubMed ID: 20093835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease?
    Grimaldi C
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):21-2. PubMed ID: 18977624
    [No Abstract]   [Full Text] [Related]  

  • 37. Adalimumab levels in an infant.
    Julsgaard M; Brown S; Gibson P; Bell S
    J Crohns Colitis; 2013 Aug; 7(7):597-8. PubMed ID: 23102835
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A; Martinsen TC; Waldum HL; Fossmark R
    Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab use in pregnancy.
    Vesga L; Terdiman JP; Mahadevan U
    Gut; 2005 Jun; 54(6):890. PubMed ID: 15888806
    [No Abstract]   [Full Text] [Related]  

  • 40. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.